Dimensional Fund Advisors
KLRS

Dimensional Fund Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Dimensional Fund Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,033
Closed -$29.5K – 3363
2024
Q4 		$29.5K Hold
3,033
– – ﹤0.01% 3317
2024
Q3 		$56.3K Hold
3,033
– – ﹤0.01% 3289
2024
Q2 		$50.8K Hold
3,033
– – ﹤0.01% 3314
2024
Q1 		$52.7K Sell
3,033
-61
-2% -$995 ﹤0.01% 3331
2023
Q4 		$48.4K Sell
3,094
-1,860
-38% -$73.3K ﹤0.01% 3349
2023
Q3 		$245K Sell
4,954
-5,159
-51% -$352K ﹤0.01% 3185
2023
Q2 		$791K Sell
10,113
-2,954
-23% -$281K ﹤0.01% 2968
2023
Q1 		$1.18M Buy
13,067
+7,576
+138% +$965K ﹤0.01% 2867
2022
Q4 		$648 Buy
5,491
+2,691
+96% +$456K ﹤0.01% 2993
2022
Q3 		$508K Sell
2,800
-1,161
-29% -$181K ﹤0.01% 3044
2022
Q2 		$356K Buy
3,961
+901
+29% +$94.5K ﹤0.01% 3143
2022
Q1 		$476K Buy
3,060
+927
+43% +$185K ﹤0.01% 3161
2021
Q4 		$635K Buy
+2,133
New +$990K ﹤0.01% 3118

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors's KLRS Position: Q1 2025 in Review

Dimensional Fund Advisors sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 3,033 shares — an estimated $29.5K sold.

Dimensional Fund Advisors first reported a position in KLRS in Q4 2021 and held it in 13 quarters. The position peaked at $1.18M in Q1 2023. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Dimensional Fund Advisors reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Dimensional Fund Advisors sold 3,033 Kalaris Therapeutics shares in Q1 2025, an estimated $29.5K.
  • Dimensional Fund Advisors first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 13 quarters.
  • Dimensional Fund Advisors's Kalaris Therapeutics position peaked at $1.18M in Q1 2023.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Dimensional Fund Advisors's 13F filing for Q1 2025, filed 13 May 2025.